Qure advances its pathology-shifting AMT-130 therapy for Huntington's disease; pivotal data and commercial launch prep target 2025 milestones.

GLP-1 receptor agonists are an important drug class and have become widely popular due to their effectiveness in weight ...

Nations that lead in clinical trials get earlier access to breakthrough therapies, shape global regulatory norms, and ...

Shares in the AI darling were trending in pre-market trading after finishing Monday’s session almost 2% higher as retail investors remain bullish on the stock. The renewed optimism can be traced to ...

In April, 2025, Demis Hassabis, the Nobel Prize-winning CEO of Google DeepMind, appeared on the US television show 60 Minutes and suggested that all diseases could be curable with the help of ...

Abuse allegations and infighting helped kill a campaign to legalize MDMA for medical use. Trumpworld is giving the therapy’s ...

We recently compiled a list of 10 Best Mid Cap Stocks to Buy According to Billionaires. Mesoblast Limited stands tenth on our ...

AI was supposed to boost drug discovery, but progress has stalled. Learn why the hype hasn’t delivered and what needs to ...

Eli Lilly & Company (NYSE: LLY) ranks among the best non-tech stocks to buy according to billionaires. Eli Lilly & Company ...

The latest health updates include Centene's improved profitability forecast, US-initiated healthcare data-sharing plans ...

Over the past decade, health insurance companies have increasingly embraced the use of artificial intelligence algorithms – ...

Institutional investors including Armistice Capital, RTW Investments, and Wellington Management have increased their exposure ...